Garogra tablets 120 mg for ulcerative colitis (carotegast methyl)

Are Garogra tablets 120 mg effective for ulcerative colitis (carotegast methyl)?

Garogra tablets are prescription ulcerative colitis tablets containing carotegrast methyl, a Japan-originated, orally available α4 integrin antagonist. Developed to address unmet needs in ulcerative colitis treatment, Garogra tablets provide a non-injectable therapeutic option for patients who experience insufficient response or intolerance to conventional therapies such as 5-ASA preparations.

Approved in Japan in 2022, carotegrast methyl represents the world’s first oral α4 integrin antagonist, offering a novel mechanism of action designed to reduce intestinal inflammation driven by lymphocyte activity.

Understanding Ulcerative Colitis and Its Impact

Ulcerative colitis is a chronic inflammatory disease of the colon characterized by persistent inflammation of the mucosal lining. Patients commonly experience cycles of remission and relapse, which can significantly impair quality of life.

Typical clinical features include abdominal pain, diarrhea, and bloody stools. Despite advances in care, the precise cause of disease onset remains unknown, and long-term disease control remains challenging for many patients.

Effective ulcerative colitis treatment aims not only to alleviate symptoms but also to reduce inflammation at the cellular level and support sustained disease control.

Mechanism of Action of Carotegrast Methyl

Garogra tablets exert their therapeutic effect through targeted modulation of immune cell migration. The active metabolite of carotegrast methyl inhibits α4β1 and α4β7 integrins expressed on lymphocytes and other inflammatory cells.

By blocking the interaction between these integrins and their ligands, VCAM-1 and MAd-CAM-1, carotegrast methyl reduces adhesion of inflammatory cells to vascular endothelial cells and limits their migration into inflamed intestinal tissue. This mechanism directly addresses lymphocyte-mediated intestinal inflammation, a central driver of ulcerative colitis pathology.

Clinical Evidence Supporting Effectiveness

The efficacy and safety of carotegrast methyl were demonstrated in a large-scale clinical trial conducted across 82 hospitals and clinics in Japan. The study enrolled 203 patients with moderately active ulcerative colitis who had an inadequate response or intolerance to mesalazine.

Key outcomes showed a significantly higher clinical response rate compared with placebo, alongside a favorable safety profile.

Notably, 45 percent of patients receiving carotegrast methyl achieved meaningful clinical improvement by week 8, including reduced disease activity and improved endoscopic findings (a reduction in Mayo Clinic score of 30% or more and 3 or more, a reduction in rectal bleeding score of 1 or more or rectal bleeding subscore of 1 or less, and an endoscopic subscore of 1 or less). Adverse events were reported less frequently in the carotegrast group than in the placebo group.

These findings were published in the peer-reviewed article “AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study” by K. Matsuoka, M. Watanabe et al., The Lancet Gastroenterology & Hepatology, July 2022.

Key Benefits of Garogra Tablets

• Oral formulation designed to meet patient demand for non-injectable therapy
• Novel mechanism targeting lymphocyte-driven intestinal inflammation
• Demonstrated clinical effectiveness in moderately active ulcerative colitis
• Favorable safety profile observed in phase 3 clinical trials

These features make carotegast tablets a meaningful therapeutic option for patients seeking alternatives within established ulcerative colitis treatment strategies.

Access and Availability

Garogra tablets have been developed under strict pharmaceutical standards and are available through authorized medical channels. Patients and caregivers seeking to buy carotegast should consult healthcare professionals to determine whether this treatment aligns with individual clinical needs.

As part of a comprehensive management approach, carotegrast methyl offers a scientifically validated option that addresses both symptom control and underlying inflammatory mechanisms in ulcerative colitis.

Package details: 336 tablets

Dosage and administration: adults should take 8 tablets (960 mg of the active ingredient) at a time, 3 times a day after meals.

Active components: carotegast methyl

Therapeutic effect: improving the symptoms of ulcerative colitis

Contraindications and precautions: Store in a dry cool place, out of reach of children.

Do not use for pregnant, possibly pregnant or breastfeeding women. Female patients who may become pregnant should use effective contraception while taking this medicine and for a specified period of time (3 days) after completing treatment. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.